Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
USA-based CNS disease specialist Supernus Pharmaceuticals has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s disease (PD). 13 October 2023
Pharmaceutical
New data from real-world evidence studies from Anglo-Swedish pharma major AstraZeneca highlight that immunocompromized (IC) individuals continue to face significant and disproportionate burdens from COVID-19. 13 October 2023
Pharmaceutical
US pharma giant Pfizer’s shares dropped 2.5% to close the regular session at $32.11, and fell a further 3.7% to $30.92 in after-hours trading, after it announced significantly changed financial guidance and updated on its government contracts for coronavirus products. 13 October 2023
Pharmaceutical
New York-based SELLAS Life Sciences is on track to complete enrollment for its Phase III REGAL study of galinpepimut-S (GPS). 13 October 2023
Pharmaceutical
Boston, USA-based contract research organization (CRO) Novotech has made two new appointments to its senior executive team. 13 October 2023
Pharmaceutical
German eye disease specialist Katairo GmbH today announced top-line results of a multi-national, multicenter, double-masked, placebo-controlled, proof of concept trial to evaluate the safety and efficacy of oral Remofuscin (soraprazen) in adults with Stargardt disease. 12 October 2023
Pharmaceutical
The British medicines regulator has initiated a new scheme designed to reduce the amount of time it takes to approve clinical trials which are deemed to be low risk. 12 October 2023
Pharmaceutical
The US Food and Drug Administration has approved US pharma giant Pfizer’s Braftovi (encorafenib) with Mektovi (binimetinib) for adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. 12 October 2023
Pharmaceutical
On Wednesday, the US Food and Drug Administration (FDA) announced the creation of a new Digital Health Advisory Committee. 12 October 2023
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello today announced positive top-line results from a Phase III pediatric clinical trial of its sublingual allergy immunotherapy tablet for the treatment of tree-pollen-induced allergic rhinoconjunctivitis. 11 October 2023
Pharmaceutical
A new product from French pharma major Sanofi’s Indian subsidiary, Soliqua (insulin glargine and lixisenatide recombinant fixed-dose combination), has recently been granted approval by the Central Drugs Standard Control Organization (CDSCO). 11 October 2023
Pharmaceutical
Patrick Branch, a Japan-based strategy consultant from LEK Consulting, provides an Expert View on the ‘new map’ for healthcare firms in Asia. 11 October 2023
Pharmaceutical
Swedish company Egetis Therapeutics has raised around $16 million in a private share placement led by US healthcare investor Frazier Life Sciences. 11 October 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk saw its shares rise 3.7% to 673.90 kroner today, on positive news announced to the stock exchange late on Tuesday. 11 October 2023
Pharmaceutical
Small molecule drugs are carving a significant niche in lung cancer treatment, an area in which AstraZeneca achieved a landmark approval from the US Food and Drug Administration (FDA) following the results of the Phase III AURA trial. 11 October 2023
Pharmaceutical
Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabian Public Investment Fund (PIF), says it has successfully completed its acquisition of a 70% stake in SaudiBio. 11 October 2023
Pharmaceutical
In the USA, the National Institutes of Health has outlined significant new investments to support research into amyotrophic lateral sclerosis (ALS). 10 October 2023
Pharmaceutical
Dutch biosynthetic pharma products specialist Centrient Pharmaceuticals is to open its new innovation lab at Spanish dermatology company Almirall’s R&D center in Barcelona. 10 October 2023
Pharmaceutical
Welcome to The Pharma Letter Podcast for a promotional episode, sponsored by Janssen, where we will deep dive into barriers and challenges in treating major depressive disorder (MDD), and finish with a few reasons for optimism. 10 October 2023
Pharmaceutical
German life sciences and pharma firm Merck KGaA today announced the presentation of new analyses from the Mavenclad (cladribine) MAGNIFY-MS study. 10 October 2023
All news
Pharmaceutical
Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named Margaret Yu its chief medical officer (CMO). 10 January 2025
Pharmaceutical
Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the global development and commercialization of a portfolio of therapies in territories outside of China and South Korea. 10 January 2025
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze